PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

$41.66+1.16 (+2.86%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PTGX Price Action

Last 7 days

1.0%

Last 30 days

-9.9%

Last 90 days

-7.0%

Trailing 12 Months

108.7%

PTGX RSI Chart

PTGX Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

14.53

Price/Sales (Trailing)

47.29

EV/EBITDA

20.89

Price/Free Cashflow

10.83

PTGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

60.0M

Rev. Growth (Yr)

-94.5%

Rev. Growth (Qtr)

12.19%

PTGX Earnings

Earnings (TTM)

170.8M

Earnings Growth (Yr)

2.62%

Earnings Growth (Qtr)

-8.47%

PTGX Profitability

EBT Margin

186.07%

Return on Equity

32.12%

Return on Assets

28.29%

Free Cashflow Yield

9.23%

PTGX Investor Care

Shares Dilution (1Y)

3.33%

Diluted EPS (TTM)

2.75

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	43.3M	60.0M
2022	46.9M	45.5M	36.0M	26.6M
2021	31.2M	27.2M	24.4M	27.4M
2020	20.0M	22.8M	25.7M	28.6M
2019	21.7M	0	14.2M	17.1M
2018	31.3M	42.5M	39.9M	30.9M
2017	0	0	0	20.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

CEO	Dr. Dinesh V. Patel Ph.D.
WEBSITE	protagonist-inc.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	106

Protagonist Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Protagonist Therapeutics Inc? What does PTGX stand for in stocks?

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protagonist Therapeutics Inc (PTGX)?

As of Tue Dec 10 2024, market cap of Protagonist Therapeutics Inc is 2.48 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers.

Is Protagonist Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTGX is over valued or under valued. Whether Protagonist Therapeutics Inc is cheap or expensive depends on the assumptions which impact Protagonist Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTGX.

What is Protagonist Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 10 2024, PTGX's PE ratio (Price to Earnings) is 14.53 and Price to Sales (PS) ratio is 47.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.